keyword
MENU ▼
Read by QxMD icon Read
search

Vasculitis rituximab

keyword
https://www.readbyqxmd.com/read/29766394/treatment-of-eosinophilic-granulomatosis-with-polyangiitis-a-review
#1
Loïc Raffray, Loïc Guillevin
Eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome) is a rare type of anti-neutrophil cytoplasm antibody-associated vasculitis. Nevertheless, eosinophilic granulomatosis with polyangiitis stands apart because it has features of vasculitis and eosinophilic disorders that require targeted therapies somewhat different from those used for other anti-neutrophil cytoplasm antibody-associated vasculitides. Considerable advances have been made in understanding the underlying pathophysiology of eosinophilic granulomatosis with polyangiitis that have highlighted the key role of eosinophils and opened new therapeutic opportunities...
May 15, 2018: Drugs
https://www.readbyqxmd.com/read/29743799/advances-in-hcv-and-cryoglobulinemic-vasculitis-in-the-era-of-daas-are-we-at-the-end-of-the-road
#2
REVIEW
Chalermrat Bunchorntavakul, Robert Mitrani, K Rajender Reddy
Hepatitis C Virus (HCV)-related Mixed Cryoglobulinemia (MC) is a unique condition with complex pathogenesis that involves HCV antigen-driven B-lymphocyte clonal proliferation and mutagenesis. Clinical spectrum of MC ranges from asymptomatic state to clinically-apparent vasculitis involving multiple organs. In the era of Direct-Acting Antiviral (DAA) therapy, patients with HCV-related MC achieve high rates of viral clearance that is commonly accompanied by an improvement in clinical symptoms as well as immunological profiles...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29738027/hydralazine-associated-adverse-events-a-report-of-two-cases-of-hydralazine-induced-anca-vasculitis
#3
Roman Zuckerman, Mayurkumar Patel, Eric J Costanzo, Harry Dounis, Rany Al Haj, Seyedehsara Seyedali, Arif Asif
Hydralazine is a direct-acting vasodilator, which has been used in treatment for hypertension (HTN) since the 1950s. While it is well known to cause drug-induced lupus (DIL), recent reports are indicating the emergence of the drug-induced anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (DIV). Herein, we describe two patients (aged 57 and 87 years) who presented with severe acute kidney injury (AKI), proteinuria, and hematuria. Both were receiving hydralazine for the treatment of hypertension...
May 7, 2018: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://www.readbyqxmd.com/read/29734473/treatment-for-hepatitis-c-virus-associated-mixed-cryoglobulinaemia
#4
REVIEW
Nuria Montero, Alexandre Favà, Eva Rodriguez, Clara Barrios, Josep M Cruzado, Julio Pascual, Maria Jose Soler
BACKGROUND: Hepatitis C virus (HCV)-associated mixed cryoglobulinaemia is the manifestation of an inflammation of small and medium-sized vessels produced by a pathogenic IgM with rheumatoid factor activity generated by an expansion of B-cells. The immune complexes formed precipitate mainly in the skin, joints, kidneys or peripheral nerve fibres. Current therapeutic approaches are aimed at elimination of HCV infection, removal of cryoglobulins and also of the B-cell clonal expansions. The optimal treatment for it has not been established...
May 7, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29725643/combination-therapy-with-rituximab-and-cyclophosphamide-for-remission-induction-in-anca-vasculitis
#5
Frank B Cortazar, Saif A Muhsin, William F Pendergraft, Zachary S Wallace, Colleen Dunbar, Karen Laliberte, John L Niles
Introduction: Remission induction in antineutrophil cytoplasmic autoantibody (ANCA) vasculitis may be complicated by slow response to treatment and toxicity from glucocorticoids. We describe outcomes with a novel remission induction regimen combining rituximab with a short course of low-dose, oral cyclophosphamide and an accelerated prednisone taper. Methods: Patients were included in this retrospective study if they had newly diagnosed or relapsing ANCA vasculitis with a Birmingham Vasculitis Activity Score for Wegener Granulomatosis (BVAS-WG) ≥3 and received a standardized remission induction regimen...
March 2018: KI Reports
https://www.readbyqxmd.com/read/29724729/long-term-efficacy-of-remission-maintenance-regimens-for-anca-associated-vasculitides
#6
Benjamin Terrier, Christian Pagnoux, Élodie Perrodeau, Adexandre Karras, Chahera Khouatra, Olivier Aumaître, Pascal Cohen, Olivier Decaux, Hélène Desmurs-Clavel, François Maurier, Pierre Gobert, Thomas Quémeneur, Claire Blanchard-Delaunay, Bernard Bonnotte, Pierre-Louis Carron, Eric Daugas, Marize Ducret, Pascal Godmer, Mohamed Hamidou, Olivier Lidove, Nicolas Limal, Xavier Puéchal, Luc Mouthon, Philippe Ravaud, Loïc Guillevin
OBJECTIVE: To compare long-term efficacy of remission-maintenance regimens in patients with newly diagnosed or relapsing antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides. METHODS: The 28-month Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis trial compared rituximab with azathioprine to maintain remission in patients with newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiitis or renal-limited ANCA-associated vasculitis...
May 3, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29722877/rituximab-for-induction-and-maintenance-therapy-of-granulomatosis-with-polyangiitis-a-single-centre-cohort-study-on-114-patients
#7
Xavier Puéchal, Michele Iudici, Ana Luisa Calich, Alexandre Vivot, Benjamin Terrier, Alexis Régent, Pascal Cohen, Claire Le Jeunne, Luc Mouthon, Philippe Ravaud, Loïc Guillevin
Objectives: To assess efficacy and safety of rituximab (RTX) induction and maintenance therapy for granulomatosis with polyangiitis (GPA) in a single-centre cohort study. Methods: All patients with active GPA, not enrolled in trials, who received ⩾1 RTX infusion(s) for induction were included. At remission, protocolized maintenance RTX infusions were given every 6 months for 18 months. Kaplan-Meier curves were used to estimate survival rates. Univariable analyses identified factors associated with remission failure and relapse, and Cox models retained independent predictors of relapse...
May 2, 2018: Rheumatology
https://www.readbyqxmd.com/read/29718732/avacopan-in-the-treatment-of-anca-associated-vasculitis
#8
Vladimir Tesar, Zdenka Hruskova
ANCA-associated vasculitis (AAV) is a rare but potentially life-threatening disease. Currently used induction treatment (cyclophosphamide or rituximab with high-dose corticosteroids) has significantly improved outcome of AAV, but is associated with high toxicity. Alternative complement pathway activation was shown to play a role in the pathogenesis of AAV, thus providing rationale for the use of avacopan, a selective inhibitor of C5a receptor, in the treatment of AAV. Areas Covered: Pharmacokinetic and pharmocodynamic properties of avacopan, clinical efficacy and safety and tolerability of avacopan in so far performed clinical trials in patients with AAV are reviewed and discussed...
May 2, 2018: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29716529/severe-localised-granulomatosis-with-polyangiitis-wegener-s-granulomatosis-manifesting-with-extensive-cranial-nerve-palsies-and-cranial-diabetes-insipidus-a-case-report-and-literature-review
#9
James E Peters, Vivek Gupta, Ibtisam T Saeed, Curtis Offiah, Ali S M Jawad
BACKGROUND: Granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis) is a multisystem vasculitis of small- to medium-sized blood vessels. Cranial involvement can result in cranial nerve palsies and, rarely, pituitary infiltration. CASE PRESENTATION: We describe the case of a 32 year-old woman with limited but severe GPA manifesting as progressive cranial nerve palsies and pituitary dysfunction. Our patient initially presented with localised ENT involvement, but despite treatment with methotrexate, she deteriorated...
May 1, 2018: BMC Neurology
https://www.readbyqxmd.com/read/29695500/comparison-of-individually-tailored-versus-fixed-schedule-rituximab-regimen-to-maintain-anca-associated-vasculitis-remission-results-of-a-multicentre-randomised-controlled-phase-iii-trial-mainritsan2
#10
Pierre Charles, Benjamin Terrier, Élodie Perrodeau, Pascal Cohen, Stanislas Faguer, Antoine Huart, Mohamed Hamidou, Christian Agard, Bernard Bonnotte, Maxime Samson, Alexandre Karras, Noémie Jourde-Chiche, François Lifermann, Pierre Gobert, Catherine Hanrotel-Saliou, Pascal Godmer, Nicolas Martin-Silva, Grégory Pugnet, Marie Matignon, Olivier Aumaitre, Jean-François Viallard, François Maurier, Nadine Meaux-Ruault, Sophie Rivière, Jean Sibilia, Xavier Puéchal, Philippe Ravaud, Luc Mouthon, Loïc Guillevin
OBJECTIVE: To compare individually tailored, based on trimestrial biological parameter monitoring, to fixed-schedule rituximab reinfusion for remission maintenance of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAVs). METHODS: Patients with newly diagnosed or relapsing granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in complete remission after induction therapy were included in an open-label, multicentre, randomised controlled trial...
April 25, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29693324/circulating-cytokine-profiles-and-anca-specificity-in-patients-with-anca-associated-vasculitis
#11
Alvise Berti, Roscoe Warner, Kent Johnson, Divi Cornec, Darrell Schroeder, Brian Kabat, Carol A Langford, Gary S Hoffman, Fernanado C Fervenza, Cees G M Kallenberg, Philip Seo, Robert Spiera, E William St Clair, Paul Brunetta, John H Stone, Peter A Merkel, Ulrich Specks, Paul A Monach
OBJECTIVES: To evaluate circulating cytokine profiles in patients with ANCA-associated vasculitis (AAV), classified by ANCA specificity (proteinase 3 (PR3)-ANCA versus myeloperoxidase (MPO)-ANCA) or by clinical diagnosis (granulomatosis with polyangiitis (GPA) versus microscopic polyangiitis (MPA)). METHODS: A panel of 29 cytokines was tested in 186 patients with active AAV at inclusion into the Rituximab in AAV (RAVE) trial. Cytokine concentrations were compared between groups within each classification system...
April 25, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29643885/anca-associated-vasculitis-in-patients-from-saudi-arabia
#12
Abdurhman Saud Al Arfaj, Najma Khalil
Objective: To explore clinical and laboratory features, therapy and outcome of antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) patients from our tertiary care center. Methods: This study of AAV patients seen in Rheumatology clinics at King Khalid University hospital (KKUH), King Saud University, Riyadh during the period 1990-2014 was carried out retrospectively. Demographic, clinical, haematological and immunological parameters along with therapy, complications and outcome were retrieved from patients' medical charts...
January 2018: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/29621029/trimethoprim-sulfamethoxazole-and-antineutrophil-cytoplasmic-antibodies-associated-vasculitis
#13
Jan Willem Cohen Tervaert
PURPOSE OF REVIEW: In antineutrophil cytoplasmic antibodies-associated vasculitis (AAV), the treatment of choice is either Rituximab or cyclophosphamide in combination with steroids. In less extended forms of AAV, however, less toxic regimens are being used.In the current review, we will focus on the role of one of these less toxic regimens, that is trimethoprim-sulfamethoxazole monotherapy as induction treatment or as maintenance therapy in AAV. RECENT FINDINGS: A substantial portion of patients with active granulomatosis with polyangiitis (GPA) limited to the upper airways can be initially controlled with trimethoprim-sulfamethoxazole (2 × 960 mg/day) monotherapy...
April 4, 2018: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/29611051/iga-vasculitis-genetics-and-clinical-and-therapeutic-management
#14
REVIEW
Miguel A González-Gay, Raquel López-Mejías, Trinitario Pina, Ricardo Blanco, Santos Castañeda
PURPOSE OF REVIEW: The purpose of the study is to perform an update on the current knowledge on genetics, clinical manifestations, and therapy in immunoglobulin A vasculitis (IgAV) (Henoch-Schönlein purpura). RECENT FINDINGS: A strong genetic predisposition in individuals with IgAV was confirmed. It was due to the association with the HLA class II region that in people of European background is mainly related to HLA-DRB1*01 allele. Recent reports support the claim that kidney disease is more common in adults than in children with IgAV...
April 2, 2018: Current Rheumatology Reports
https://www.readbyqxmd.com/read/29611001/eosinophilic-granulomatosis-with-polyangiitis-newer-therapies
#15
REVIEW
Erika P Navarro-Mendoza, Gabriel J Tobón
PURPOSE OF REVIEW: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic disseminated vasculitis associated with extravascular granulomas in patients suffering from asthma and tissue eosinophilia. Current therapies to achieve remission and prevent relapse include glucocorticoids and immunosuppressants like cyclophosphamide. RECENT FINDINGS: With the right treatment, clinical prognosis is favorable, so concerted efforts have been made in recent years to find new alternatives for treating severe EGPA...
April 2, 2018: Current Rheumatology Reports
https://www.readbyqxmd.com/read/29564565/imatinib-mesylate-use-in-refractory-eosinophilic-granulomatosis-with-polyangiitis-a-literature-review-and-a-case-report
#16
REVIEW
Tatiana V Beketova, Mikhail Y Volkov, Evgeniy A Naryshkin, Tatiana M Novoselova, Evgeniy L Nasonov
Recent advances in pharmacology have greatly expanded the drug repertoire for treatment of anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystemic disorder, a type of the ANCA-associated vasculitis. Important features of this disease are eosinophilia and anti-myeloperoxidase ANCA presence in around 30-70% of patients. Primary therapy of EGPA includes steroids and cytotoxic drugs, e.g., cyclophosphamide, azathioprine, or methotrexate...
March 21, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29558353/-cryoglobulins-and-cryoglobulinemic-vasculitis
#17
Dorota Suszek, Maria Majdan
Cryoglobulinemia is defined as the presence of cryoglobulins in the blood. Cryoglobulinemia is often observed in the course of many diseases (infection, hematological disorders, autoimmune disorders) or has an idiopathic character. The classification of cryoglobulinemia is based on the immunological analysis of cryoglobulins and the activity of the rheumatoid factor (RF). The presence of cryoglobulins may induce cryoglobulinemic vasculitis (CV) which manifests with skin changes, arthritis and the dysfunction of internal organs...
2018: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29546609/igg4-related-disease-beyond-glucocorticoids
#18
REVIEW
Mitsuhiro Akiyama, Tsutomu Takeuchi
IgG4-related disease is a heterogeneous immune-mediated fibroinflammatory condition that can affect every single organ. This disease is more prevalent in the elderly (the mean age of patients is above 60 years) and the prevalence rate is estimated to be over 4.6 per 100,000 population. Before making a diagnosis, the exclusion of malignancies, lymphoma, anti-neutrophil cytoplasmic antibody-associated vasculitis, multicentric Castleman disease, and other mimickers is crucial for appropriate treatment. Broad management guidelines have been published emphasizing the need for prompt treatment and the use of glucocorticoids as first-line drug therapy for induction of remission...
March 15, 2018: Drugs & Aging
https://www.readbyqxmd.com/read/29545130/-renal-involvement-of-cryoglobulinemia
#19
Alexandre Karras
Cryoglobulins are immunoglobulins that undergo reversible precipitation at low temperatures. They can induce systemic vasculitis, characterized by purpuric cutaneous lesions, arthritis, peripheral neuropathy, hypocomplementemia and glomerular disease. Renal pathology reveals membranoproliferative glomerulonephritis, with particularly intense mesangial cell proliferation and infiltration by macrophages, associated with intracapillary thrombi. This renal disease presents as a nephritic syndrome, with heavy proteinuria, haematuria severe hypertension and rapidly progressive kidney failure that can lead to end-stage renal disease...
April 2018: Néphrologie & Thérapeutique
https://www.readbyqxmd.com/read/29530330/reducing-glucocorticoid-duration-in-anca-associated-vasculitis-a-pilot-trial
#20
Eli M Miloslavsky, John L Niles, Zachary S Wallace, Frank B Cortazar, Ana Fernandes, Karen Laliberte, John H Stone
OBJECTIVE: Therapeutic advances in ANCA-associated vasculitis (AAV) have improved patient survival, but mortality rates remain higher than the general population. Glucocorticoids contribute to AAV morbidity and mortality. We examined whether an 8-week glucocorticoid course in combination with rituximab (RTX) would induce disease remission in patients with AAV. METHODS: Patients with active AAV received an 8-week prednisone taper and RTX 375mg/m2 weekly for 4 weeks...
February 3, 2018: Seminars in Arthritis and Rheumatism
keyword
keyword
40034
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"